CBPR277X2101

Conditions: Part 2: Atopic Dermatitis (AD)Part 3: Netherton Syndrome (NS)
MedDRA version: 14.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858
MedDRA version: 14.1Level: PTClassification code 10062909Term: Netherton's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

Registration Number: EUCTR2011-000917-38-DE

Lead Sponsor: ovartis Pharma Services AG

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 85

Inclusion Criteria

Subjects eligible for inclusion in this study have to fulfill all of the following criteria. Other protocol-defined inclusion criteria apply in addition to those listed hereafter:

Part 1:
1.Written informed consent must be obtained before any assessment is performed.
2.Healthy male and female subjects of non childbearing potential, 18 to 65 years of age inclusive and in good health
3.Subjects must weigh at least 50kg to participate in the study, and must have a body mass index (BMI) within the range of 18-35kg/m2.
4.Study subjects must be able to communicate well with the investigator, to understand and comply with the requirements of the study.

Part 2:
1.Written informed consent must be obtained before any assessment is performed.
2.Male and female subjects, 18 to 65 years of age inclusive and having passed screening examinations
3.Presence of atopic dermatitis confirmed by Itchy skin condition in the past 12 months (must have)
Plus three or more of the following:
•History of involvement of the skin creases
•Personal history of asthma or hay fever
•History of generally dry skin in the past year
•Onset before age of 2 years
•Visible flexural dermatitis
4.Diagnosis of at least moderate atopic dermatitis by the IGA of the to-be-treated area at screening; and a 250 cm2 to-be-treated area of skin containing at least ~50% AD affected skin. The 250 cm2 treatment area is to be ideally situated on the forearm including the antecubital fossa with a total lesional sign score (TLSS) of at least 10 at screening. Alternative locations for the treatment area are detailed in the protocol. Areas that
must not be chosen are: hands and feet, head and neck, back, armpits and the groin.
5.A total lesional sign score (TLSS) at baseline of 2-4 within the study treatment area.
6.Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18-42 kg/m2.
7.Study subjects must be able to communicate well with the investigator, to understand and comply with the requirements of the study

Part 3 Cohort A, AA and AB (patients with Netherton Syndrome):
• Patients with Netherton syndrome, male and female subjects, 18 to 65 years of age inclusive and having passed screening examinations
• Confirmed diagnosis of Netherton syndrome (SPINK5 mutation or LEKTI deficiency in the skin).
• Minimum total lesional sign score NS (TLSS-NS) of 5-9 for two selected target areas at baseline. The TLSS-NS values need to be similar between the two areas at baseline.

Other protocol-defined inclusion/exclusion criteria may apply. Refer to protocol for details.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 85
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Subjects fulfilling any of the following criteria are not eligible for inclusion in this study. Other protocol-defined exclusion criteria apply in addition to those listed hereafter:

Part 1:
1.Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
2.History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction.
3.A history of clinically significant ECG abnormalities, or ECG abnormalities at Screening or Baseline.
4.History of malignancy of any organ system, treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
5.Use of any prescription drugs, herbal supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing.
6.Total WBC count which falls outside the range of 4500–11,000/µl, or platelets <100,000/µl, or hemoglobin levels below 12.0 g/dl at screening.
7.Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation.
8.Recent and/or recurrent history of autonomic dysfunction
9.Liver disease or liver injury as indicated by abnormal liver function tests
10.History or presence of impaired renal function
11.Evidence of urinary obstruction or difficulty in voiding at screening.
12.History of hypertrophic scarring.
13.History of immunodeficiency diseases.

Part 2:
1.Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
2.History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction.
3.History of abnormal skin reactivity to UV light. Unusual exposure to UV light in the previous 3 weeks to study start (screening), including tanning and sun beds.
4.Pregnant or nursing (lactating) women.
5.Women of child-bearing potential must use highly effective contraception (as further defined in study protocol) during the study and the duration of the study.
6.Use of topical prescription treatment for eczema (topical corticosteroids, calcineurin inhibitors, antibiotics, etc...) on the selected study treatment area within 1 week prior to initial dosing of topical corticosteroids (TCS).
7.Recent previous treatment with phototherapy, biological therapy, immunosuppressive agents such as cyclosporine, mycophenolate, pimecrolimus or tacrolimus. A washout period will be required for such patients to be eligible to participate in the trial.
8.Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation.
9.History of malignancy of any organ system, treated or untreated, within the past 5 years.
10.History of clinically significant ECG abnormalities or Screening/Baseline ECG abnormalities
11.Inability or unwillingness to undergo multiple venipunctures
12.History of hypertrophic scarring.

Part 3 Cohorts A, AA & AB (patients with Netherton Syndrome):
• History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction.
• History of abnormal skin reactivity to UV light. Unusual exposure to UV light in the previous 3 weeks to study start (